- Home
- CRVS vs NYXH Comparison
CRVS vs NYXH Comparison
Compare CRVS & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- NYXH
- Stock Information
- Founded
- CRVS 2014
- NYXH 2009
- Country
- CRVS United States
- NYXH Belgium
- Employees
- CRVS N/A
- NYXH N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- NYXH Medical/Dental Instruments
- Sector
- CRVS Health Care
- NYXH Health Care
- Exchange
- CRVS Nasdaq
- NYXH Nasdaq
- Market Cap
- CRVS 305.4M
- NYXH 290.9M
- IPO Year
- CRVS 2016
- NYXH 2021
- Fundamental
- Price
- CRVS $4.10
- NYXH $7.31
- Analyst Decision
- CRVS Strong Buy
- NYXH Strong Buy
- Analyst Count
- CRVS 4
- NYXH 4
- Target Price
- CRVS $15.00
- NYXH $14.50
- AVG Volume (30 Days)
- CRVS 445.0K
- NYXH 44.1K
- Earning Date
- CRVS 08-12-2025
- NYXH 08-18-2025
- Dividend Yield
- CRVS N/A
- NYXH N/A
- EPS Growth
- CRVS N/A
- NYXH N/A
- EPS
- CRVS N/A
- NYXH N/A
- Revenue
- CRVS N/A
- NYXH $4,716,818.00
- Revenue This Year
- CRVS N/A
- NYXH $209.22
- Revenue Next Year
- CRVS N/A
- NYXH $219.37
- P/E Ratio
- CRVS N/A
- NYXH N/A
- Revenue Growth
- CRVS N/A
- NYXH N/A
- 52 Week Low
- CRVS $2.47
- NYXH $5.55
- 52 Week High
- CRVS $10.00
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- CRVS 44.93
- NYXH 43.37
- Support Level
- CRVS $4.58
- NYXH $7.00
- Resistance Level
- CRVS $4.98
- NYXH $7.59
- Average True Range (ATR)
- CRVS 0.23
- NYXH 0.33
- MACD
- CRVS -0.04
- NYXH -0.08
- Stochastic Oscillator
- CRVS 13.79
- NYXH 27.89
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.